ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 760

Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis

Miki Takata1, Elena Pachera1, Anastasiia Kozlova1, Astrid Jüngel1, Tobias Messemaker2, Jeska de Vries-Bouwstra2, Tom W.J. Huizinga3, Fina Kurreeman2 and Oliver Distler4, 1Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, 3Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 4Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: fibrosis and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Long noncoding RNAs (lncRNAs) represent a class of transcripts longer than 200 nucleotides that are not translated into proteins. In recent years, antisense (AS) lncRNAs have increasingly been recognized as important regulators of their sense genes and they have been found to play key roles in the pathogenesis of several diseases. However, the role of AS lncRNAs in SSc is still unknown. Our previous study identified two AS lncRNAs in SSc skin biopsies namely HAND2-AS1 and OTUD6B-AS1. Here we aim to characterize the functional relevance of these AS lncRNAs.

Methods: Sense and AS gene expression was analyzed by qPCR in RNA samples of HC and SSc dermal fibroblasts (Fb). Dermal Fb were stimulated with different profibrotic cytokines and growth factors like TGFβ, PDGF and IL-4 at physiological concentrations. Function of AS lncRNAs was analyzed by qPCR and Western Blot (WB) in HC dermal Fb and human pulmonary artery smooth muscle cells (HPASMC) transfected with locked nucleic acid antisense oligonucleotides (LNA GapmeRs).

Results: RNA sequencing analysis of skin biopsy revealed consistent and significant downregulation of HAND2-AS1 and OTUD6B-AS1 expression. In SSc and HC dermal Fb, no difference was recorded in the basal level of HAND2-AS1, HAND2, OTUD6B-AS1 and OTUD6B expression. However, HAND2 and HAND2-AS1 expression in SSc dermal Fb was significantly downregulated after TGFβ and IL-4 stimulation (n=4-5, p<0.05, up to 0.09 fold reduction). HAND2-AS1 expression was also significantly downregulated after PDGF stimulation (n=4, p<0.05, up to 0.12 fold reduction) and HAND2 expression had the same trend. OTUD6B expression in SSc dermal Fb was significantly downregulated after PDGF stimulation (n=7, p<0.05, up to 0.16 fold reduction) and OTUD6B-AS1 expression was also decreased. OTUD6B-AS1 expression was significantly downregulated after IL-4 stimulation (n=4, p<0.05, up to 0.52 fold reduction). Importantly, HAND2-AS1 knockdown significantly reduced collagen 1A1, fibronectin and α-smooth muscle actin (αSMA) mRNA in dermal Fb (p<0.05). Downregulation of fibronectin expression was also confirmed after HAND2-AS1 knockdown by WB analysis (n=4). In contrast to HAND2-AS1, OTUD6B-AS1 knockdown did not affect extracellular matrix production. However, we observed effects on cell cycle regulation after OTUD6B-AS1 knockdown. OTUD6B-AS1 knockdown in Fb and HPASMC significantly increased OTUD6B, and cell cycle regulators c-MYC, Cyclin D1 and Cyclin D2 mRNA (n=6, p<0.05). Upregulation of OTUD6B, c-MYC and Cyclin D1 in HPASMC was also confirmed after OTUD6B-AS1 knockdown by WB analysis (n=2).

Conclusion: This is the first report analyzing the functional role of AS lncRNAs in SSc. These results point to an important role of HAND2-AS1 in extracellular matrix production and of OTUD6B-AS1 in cell cycle progression.


Disclosure: M. Takata, None; E. Pachera, None; A. Kozlova, None; A. Jüngel, None; T. Messemaker, None; J. de Vries-Bouwstra, None; T. W. J. Huizinga, None; F. Kurreeman, None; O. Distler, Actelion, 5,Bayer, 5,Biogen Idec, 5,Boehringer Ingelheim, 5,ChemomAb, 5,espeRare Foundation, 5,Genentech/Roche, 5,GlaxoSmithKline, 5,Inventiva, 5,Lilly, 5,Medac, 5,MedImmune, 5,Mitsubishi Tanabe Pharma, 5,Pharmacyclics, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Sanofi, 5,Sinoxa, 5,UCB in the area of potential treatments of scleroderma and its complications, 5,Patent mir-29 for the treatment of systemic sclerosis licensed, 5,Actelion, 2,Bayer, 2,Biogen Idec, 2,Boehringer Ingelheim, 2,ChemomAb, 2,espeRare Foundation, 2,Genentech/Roche, 2,GlaxoSmithKline, 2,Inventiva, 2,Lilly, 2,Medac, 2,Medimmune, 2,Mitsubishi Tanabe Pharma, 2,Pharmacyclics, 2,Novartis, 2,Pfizer Inc, 2,Sanofi, 2,Sinoxa, 2,UCB in the area of potential treatments of scleroderma and its complications, 2,Patent mir-29 for the treatment of systemic sclerosis licensed, 2.

To cite this abstract in AMA style:

Takata M, Pachera E, Kozlova A, Jüngel A, Messemaker T, de Vries-Bouwstra J, Huizinga TWJ, Kurreeman F, Distler O. Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/antisense-long-noncoding-rna-hand2-as1-and-otud6b-as1-have-important-roles-in-the-pathogenesis-of-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antisense-long-noncoding-rna-hand2-as1-and-otud6b-as1-have-important-roles-in-the-pathogenesis-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology